Rumors that Celgene Corporation is in talks to acquire Juno Therapeutics caused Juno’s stock to rocket more than 50 percent to $68.80 in premarket trading.
Based on the closing of IMS Health and Quintiles common stock prices on May 2, 2016, the equity market capitalization of the joined companies is more than $17.6 billion and the enterprise value is more than $23 billion.
Investment bank Lazard is working with Sanofi’s management to prepare a sale or listing of its Merial animal health unit, aiming to land the leading advisory job for the deal, which could value the business at up 12 billion euros ($12.7 billion), sources familiar with the matter said. Lazard is expected to win the role […]
NEW YORK – A Chinese drug manufacturing facility run by Pfizer Inc. (PFE) is under scrutiny by the U.S. Food and Drug Administration (FDA) after regulators discovered the use of expired materials and a second set of quality and manufacturing records that did not match official documentation, Bloomberg reported this morning. However, Pfizer said […]
After months of speculation on who Pfizer Inc. (PFE) will attempt to buy are now officially over — sort of. It has been confirmed that Pfizer Inc. and Allergan Plc (AGN), according to the Wall Street Journal, are discussing a potential merger. The two companies have declined to comment. Analysts have been speculating on […]
Analysts are confident the U.S. Food and Drug Administration (FDA) will soon approve Novo Nordisk’s new long-lasting insulin drug Tresiba — just as they were before the drug was first rebuffed two years ago. Tresiba is considered as a future blockbuster for the Danish company, the Nordic region’s most valuable, but the U.S. regulator asked […]
New market data is showing a renewed and ravenous demand for options tied to declines in an exchange-traded fund tracking biotech companies, according to Bloomberg data, which hit the highest level in three years last week. Biotech is continuing its scorching pace of growth, with the NASDAQ Biotechnology Index (NBI) up more than 25 percent […]